The second injection of cells was administered at the same site within 7 to 10 days.
Two days following the last dose of fludarabine, a second infusion of T cells was administered.
On day 0 an unmanipulated graft containing 182 × 109 leukocytes, containing 769 × 106 cells cells, was administered.
Three ml of feline leukemia virus (105.5 PFU/ml), strain 61E (subtype A) grown on NCE-F161 cells, was administered via the oronasal route.
To assess p53 protein stability, 50 μg/ml cycloheximide, an inhibitor of protein synthesis in eukaryotic cells, was administered to A549 cells which were transiently transfected with different expression plasmids, pEGFPN1, pEGFP-NP with or without pCDNA3.1-RNF43-Flag-HA pCDNA3.1-RNF43-Flag-HA pCDNA3.1-RNF43-Flag-HA pCDNA3.1-RNF43-Flag-HA
Equal volumes of T24 cells and matrigel were combined to enhance the tumorigenic activity of the cells, before a single anterior-dorsolateral subcutaneously inoculation consisting of 100 μL of the mixture containing 1 × 10 cells was administered to each mouse.
Immediately after FACS, 1 µl of PBS that contained 10 of CD24−CD31−CD45−GFP+ cells was administered transcranially at the following coordinates: AP = +0.75 mm, L = −1.1 mm and DV = −2.7 mm into anaesthetized C57Bl6J mice.
route (twice daily) to "prime" the body, 1 mL hESCs (<16 million cells) were administered via intravenous (i.v).v
The cells were administered i.t. between the 5th and 14th day of life without signs of dose-limiting toxicity or severe adverse effects.
Nonetheless, although the CAR also engages mouse αvβ6, mild and reversible toxicity was only observed when supra-therapeutic doses of CAR T cells were administered parenterally.
